La UB, the CSIC and UAB licensing a patent the company Janus Developments for the treatment of inflammatory diseases.
the results of proprietary research might be useful in the medium term in the treatment of various inflammatory diseases.
Barcelona, January of 2013.- after a long history of collaboration between three research groups of the UB, the CSIC and UAB interference (siRNA) nucleic acids research, found the solution when it comes to inhibit, among others, genes involved in inflammatory diseases, such as e.g. those related to the action of the Tumor Necrosis Factor-alpha (TNF-alpha). As result of this project in 2010 applied for a patent that has been recently licensed the company Janus Developments SL
the results obtained so far do foresee that, in the long run, these products might be useful in the treatment of inflammatory diseases such as Crohn’s disease, Ulcerative Colitis, asthma, psoriasis and even some types of oncological diseases. Since in these diseases, the TNF-alpha promotes disease state, it is clear that the regulation of this factor could allow a considerable improvement in patients when it can finally be applied after the clinical development.
Patented search results have been obtained from the joint research of the research groups of universities and centers. The CSIC, has participated the Group’s chemistry of nucleic acids, led by Dr. Ramon Eritja, Institute of chemical advanced (IQAC), by the UB, participated in inflammation and Diabetes metabolic regulation group, led by Dr. José Carlos Perales, and UAB participated the research group in inflammation and tolerance, led by Dr. Ester Fernández.
Janus Developments SL, a company that aims to bring basic industry research so that inventions could actually reach end-users, has licensed this patent in order to continue maturing the development of this potential therapy to start pre-clinical studies. In the future, is expected to incorporate other partners to the project to finance its full clinical development.
The FBG as transfer of knowledge, technology and innovation of the UB Center has led negotiations of the research group of the UB with the Janus Developments company.
